Form 8-K - Current report:
SEC Accession No. 0000950170-25-033071
Filing Date
2025-03-05
Accepted
2025-03-05 07:15:08
Documents
13
Period of Report
2025-03-05
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K tcrx-20250305.htm   iXBRL 8-K 46422
2 EX-99.1 tcrx-ex99_1.htm EX-99.1 190027
3 GRAPHIC img207367504_0.jpg GRAPHIC 85034
  Complete submission text file 0000950170-25-033071.txt   489735

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT tcrx-20250305.xsd EX-101.SCH 30852
15 EXTRACTED XBRL INSTANCE DOCUMENT tcrx-20250305_htm.xml XML 4708
Mailing Address 880 WINTER STREET WALTHAM MA 02451
Business Address 880 WINTER STREET WALTHAM MA 02451 857-399-9500
TScan Therapeutics, Inc. (Filer) CIK: 0001783328 (see all company filings)

EIN.: 825282075 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40603 | Film No.: 25708814
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)